ZSAN
Zosano Pharma Corporation
Set alert
0.56 0.00 0.00%
0.46 Day range 0.635
52-week range unavailable
- Open
- 0.5188
- Prev close
- 0.5576
- Mkt cap
- 2.73M
- Vol
- 1.16M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.46
- High
- 0.635
- Forward P/E
- -6.20
- Beta
- 3.29
- Short ratio
- 1.18
- Inst. own
- 8.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 13, 2022
- 50-d avg
- 1.53
- 200-d avg
- 0.92973
- 1y target
- 21.00
Key statistics
- Market cap
- 2.73M
- Enterprise value
- -4.66M
- Trailing P/E
- 0.00
- Forward P/E
- -6.20
- PEG ratio
- 0.00
- Price / sales
- 4.15
- Price / book
- 0.19
- EPS (TTM)
- -15.69
- Beta
- 3.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 659.00K
- Revenue growth
- -48.80%
- Free cash flow
- -18.03M
- Total cash
- 13.53M
- Total debt
- 6.04M
- Return on equity
- -192.97%
- Shares outstanding
- 4.90M
- Short % of float
- 8.17%
- 50-day average
- 1.53
- 200-day average
- 0.92973
Analyst view
Consensus: hold
Hold
Price target (mean) 21.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
May 13, 2022
Expected May 13, 2022. Consensus EPS estimate -0.02.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 13, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 17, 2022 | Dec 1, 2021 | -2.45 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -2.45 | — | — | — |
| Aug 10, 2021 | Jun 1, 2021 | -2.45 | — | — | — |
| May 12, 2021 | Mar 1, 2021 | -2.45 | — | — | — |
| Mar 11, 2021 | Dec 1, 2020 | -2.45 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 23, 2022 | BTIG | down | Buy | Neutral |
| Mar 15, 2021 | Maxim Group | main | — | Buy |
| Nov 25, 2020 | HC Wainwright & Co. | main | — | Buy |
| Oct 2, 2020 | HC Wainwright & Co. | main | — | Buy |
| Apr 9, 2020 | H.C. Wainwright | init | — | Buy |
| Mar 27, 2020 | BTIG | main | — | Buy |
About Zosano Pharma Corporation
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zosanopharma.com
News
- Microneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass Technologies
- Why Zosano Pharma Shares Are Getting Hammered Today
- Zosano Pharma Reports First Quarter 2022 Financial Results
- 81 Biggest Movers From Yesterday
- Zosano Pharma Announces Additional Workforce Layoff
- Zosano Pharma Provides Corporate Update
- 26 Stocks Moving in Monday's Pre-Market Session
- Is Zosano Pharma (ZSAN) Stock Really Up 3,000% Today?
- Zosano Pharma (ZSAN) Stock: 1-For-35 Reverse Split Goes Into Effect
- Zosano Pharma Announces Reverse Stock Split Effective Today
Your note
Sign in to keep a note on ZSAN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELMS STEVEN A | Director | Stock Award(Grant) | Jun 9, 2021 | 2,740,730 |
| GRAIS LINDA S | Director | Stock Award(Grant) | Jun 9, 2021 | 22,500 |
| GREATHOUSE KENNETH R | Director | Sale | Nov 22, 2021 | 43,500 |
| HAGAN JOSEPH PATRICK | Director | Stock Award(Grant) | Jun 9, 2021 | 22,500 |
| KELLERMAN DONALD J | Officer | Sale | Mar 30, 2022 | 56,331 |
| LEWIS HAYLEY | Officer | Sale | Jun 3, 2021 | 49,779 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 18.37% | 900,316 | 7.09M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 3.00% | 147,109 | 1.16M | Mar 30, 2022 |
| Aisling Capital Management LP | 1.58% | 77,662 | 611.59K | Mar 30, 2022 |
| Blackrock Inc. | 1.20% | 58,602 | 461.49K | Mar 30, 2022 |
| State Street Corporation | 0.25% | 12,467 | 98.18K | Mar 30, 2022 |
| Renaissance Technologies, LLC | 0.15% | 7,115 | 56.03K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.84% | 90,042 | 709.08K | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 0.98% | 47,964 | 377.72K | Mar 30, 2022 |
| Fidelity Extended Market Index Fund | 0.32% | 15,802 | 124.44K | Mar 30, 2022 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.08% | 4,093 | 32.23K | Mar 30, 2022 |
| Vanguard Balanced Index Fund | 0.08% | 3,745 | 29.49K | Mar 30, 2022 |
| Fidelity Total Market Index Fund | 0.08% | 3,735 | 29.41K | Mar 30, 2022 |